The same price is already available on Novo Nordisk\u2019s direct-to-consumer website, as well as at Walmart and CVS<\/p>\n<\/h3>\n
By I. Edwards HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Oct. 6, 2025 (HealthDay News) \u2014 Costco shoppers will be able fill prescriptions for Ozempic and Wegovy \u2014 two of the most popular weight loss and diabetes drugs \u2014 at a discount.<\/p>\n
Novo Nordisk<\/a>, the maker of both medications, announced Friday that the warehouse retailer will sell a four-week supply of the injections for $499 out of pocket at its more than 600 U.S. Costco pharmacies.<\/p>\n The same price is already available on Novo Nordisk\u2019s direct-to-consumer website, as well as at Walmart and CVS pharmacies.<\/p>\n \u201cWe want to make sure we offer the real, authentic Wegovy and Ozempic where patients seek care,\u201d David “Dave” Moore<\/a>, president of Novo Nordisk U.S., told NBC News<\/em>. \u201cWe know that Costco is a trusted brand.\u201d<\/p>\n The move is part of Novo Nordisk\u2019s effort to expand legitimate access to its medications and compete with compounding pharmacies and medical spas that sell unapproved versions.<\/p>\n Costco members with a valid prescription can pay the $499 self-pay price, while insurance coverage will vary by plan. Executive members and Costco credit card holders may also earn cash back through the retailer\u2019s pharmacy rewards program.<\/p>\n Ozempic<\/a> and Wegovy are part of a class of drugs known as GLP-1 receptor agonists, which mimic a hormone that helps regulate blood sugar and appetite.<\/p>\n Originally developed to treat diabetes, they\u2019ve become popular for weight loss and have shown promise in lowering stroke and heart risk and improving liver health in recent studies.<\/p>\n “This will definitely improve one of the issues with access,” Dr. Rekha Kumar<\/a>, endocrinologist at Weill Cornell Medicine in New York City, told NBC News.<\/em><\/p>\n Though she noted it doesn\u2019t solve issues of insurance coverage and cost, it creates options for patients.<\/p>\n “There is another place that people can get the medicine that you know isn\u2019t their retail pharmacy, isn\u2019t an online tele-health pharmacy, but a large store that many people in the United States go to,\u201d Kumar said.<\/p>\n Still, affordability remains a major barrier. While some insured patients can pay as little as $25 per month, many plans still don’t cover GLP-1 drugs prescribed for obesity.<\/p>\n Notably, only 13 states include them in Medicaid coverage, according to KFF<\/a>, a nonpartisan health policy organization.<\/p>\n \u201cThe people who have the greatest need for these medications are precisely the people who are in lower socioeconomic strata who have either poor insurance or no insurance, and don\u2019t have the discretionary funds to be spending on medications,\u201d Dr. Harlan Krumholz<\/a>, a cardiologist at Yale School of Medicine in New Haven, Conn., told NBC News.<\/em><\/p>\n \u201cIf we really want to make the biggest difference on the health of the nation, we have to make sure that the people who would benefit the most have access to medications that are being shown to be beneficial,” he said.<\/p>\n More information<\/strong><\/p>\n Harvard Health has more on GLP-1<\/a>.<\/p>\n